The publication of the Hepcidin Harmonization study from Lisa N. van der Vorm et al, was accepted by Clinical Chemistry. The print version we will show on this pdf.

DRG´s Hepcidin 25 (bioactive) HS ELISA, EIA-5782 was part of this study. You can find it in the paper, please refer to reference number IC-6 (immunochemical measurement procedure 6), Dorine Swinkel´s home-brew ELISA is IC-2, Eli Lilly´s Sandwich Assay is IC-3, Bachem´s assay has IC-4, and Intrinsic LifeSciences is IC-5.

Dr. Matthias Herkert, Director R&D of DRG: "The results of the study are very encouraging for the DRG team and will be motivation for all to keep high quality standards for our products!"

Dr. Herkert summarized this paper as follows:

Hepcidin plasma concentrations differ substantially between various procedures on the market (mass spectrometry or immunoassays). This is due to the lack of certified reference material. The Worldwide Hepcidin Assay Harmonization study intended to establish and test a commutable reference material.

DRG was invited to participate in the study together with other suppliers of Hepcidin-25 immunoassays and mass spectrometry procedures (11 measurement procedures in total). As expected, absolute Hepcidin concentrations differed considerably by a mean factor 7 difference between the extreme procedures. However, DRG`s Hepcidin-25 (bioactive) HS ELISA showed excellent correlation to reference mass spectrometry results. Furthermore, the DRG assay showed good precision (mean intra-CV of 5.7 %) and linearity of dilution (Pearson correlation coefficient r = 0.997). A commutable candidate reference material with robust stability and compatibility to all procedures was identified and will be further validated in 2016. In conclusion, a harmonization and standardization of all procedures to quantify Hepcidin-25 should be expected in the near future. This will facilitate comparison of various studies using Hepcidin as a biomarker, and support medical research and its translation to the clinic.

09-Jan-2012ARAB HEALTH 2012DRG will exhibit at ARAB HEALTH 2012 in Dubai. Please book your meeting with us
More...

07-Nov-2011MEDICA 2011DRG will exhibit at MEDICA in same booth location Hall 3 A69. Please book your meeting with us.
More...

21-Sep-2011Alzheimer's ResearchThe first test worldwide for the determination of serum auto-antibodies against Amyloid peptides is presented by DRG
More...

03-Sep-2011New DRG Building officially dedicated!The official dedication of the new addition to the DRG building took place on September 2nd in Marburg.
More...

29-Jun-2011AACC 2011DRG International Inc. exhibits again at the AACC Clinical Lab Expo 2011 and will also present a poster in new fields of research.
More...

23-May-2011Medal of HonorCyril Geacintov, President and CEO of DRG Intl. awarded the Ellis Island Medal of Honor for his achievements as a business leader of diverse ethnic origin.
More...

14-Apr-2011New certificate for DRG list B products available!DRG has successfully passed this years surveillance audit (TUV Rheinland) and has extended the list of CE approved List B products. We are proud to present the new certificate.
More...

13-Oct-2010The Cornerstone Of The New DRG Building Addition In Marburg The DRG Group is pleased to announce that the cornerstone of the new DRG building addition in Marburg was set in place
More...

11-Oct-2010DRG Acquires DIMA Diagnostica from bioMérieuxDRG Instruments will acquire the microtiter plate Elisa production, including existing finished stock, raw materials, from DIMA, which is based in Germany.
More...

11-Aug-2010DRG Renin-ELISA -
The worldwide first Sandwich-ELISA for the non-radioactive quantification of active ReninIn the United States, one third of the American adults have high blood pressure or hypertension, and among those, almost one third even do not know that they had the condition.
More...

21-Jul-2010DRG to launch DRG:Hybrid-XL at AACC DRG offers Preview of major new fully-automated immunodiagnostic and clinical chemistry automatic reader.
More...